Efficacy and involvement gut microbiota of atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
Not Applicable
- Conditions
- nresectable advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000043934
- Lead Sponsor
- Kurume university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with impaired liver reserve (Child-Pugh class C) 2. Patients with refractory ascites 3. Patients judged ineligible by the principal investigator and sub-investigators 4. Patients for whom local therapy is indicated
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association with gut microbiota composition and efficacy of atezolizumab and bevacizumab therapy in patients with unresectable advanced hepatocellular carcinoma.
- Secondary Outcome Measures
Name Time Method Incidence of adverse events, concentration of cytokines and chemokines in the blood, and ratio of tumor immune-related cells in the blood.